Intercell's revenues surge on back of Ixiaro
This article was originally published in Scrip
Executive Summary
Intercell's second-quarter revenues rose by 65% to €14.9 million following the approval of its first product on the market, Ixiaro, a vaccine against Japanese encephalitis.